Virbac SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Virbac SA Issues FY 2013 Organic Growth and Operating Profitability Guidance; Proposes FY 2012 Dividend
Virbac SA announced that it expects 5 to 7% organic growth and a further 0.5 point improvement of operating profitability in fiscal year 2013. The Company also announced that a dividend of EUR 1.90 per share for fiscal year 2012, as compared to EUR 1.75 in fiscal year 2011, shall be proposed at the next Annual Shareholders Meeting and will be payable on June 26, 2013.
Latest Key Developments in Pharmaceuticals
- Adamis Pharmaceuticals Corp announces pricing of public offering shares
- Merrimack Pharmaceuticals Inc announces encouraging clinical data from expanded phase one study of MM-302 for the treatment of advanced her2-positive breast cancer
- Perrigo Co And Elan Corporation plc receive Irish High Court approval for Perrigo's proposed acquisition of Elan
- Torrent Pharmaceuticals Ltd to acquire indian branded formulations business of Elder Pharmaceuticals Ltd
- Share this
- Digg this